{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:22:59Z","timestamp":1791894179515,"version":"4.3.4"},"reference-count":311,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01418","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T09:54:20Z","timestamp":1561456460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":207,"title":["Pemphigus: Current and Future Therapeutic Strategies"],"prefix":"10.3389","volume":"10","author":[{"given":"Dario","family":"Didona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Eming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fmed.2018.00218","article-title":"The evolving story of autoantibodies in pemphigus vulgaris: development of the \u201csuper compensation hypothesis\u201d","volume":"5","author":"Sinha","year":"2018","journal-title":"Front Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/archderm.134.8.971","article-title":"The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus","volume":"134","author":"Vu","year":"1998","journal-title":"Arch Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms18122532","article-title":"Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy","volume":"18","author":"Paolino","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1610-0387.2011.07809.x","article-title":"Autoimmune bullous skin diseases Part 2: diagnosis and therapy","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges."},{"key":"B8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1610-0387.2011.07793.x","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges."},{"key":"B9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0030-4220(74)90365-X","article-title":"Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion","volume":"38","author":"Pisanti","year":"1974","journal-title":"Oral Surg Oral Med Oral Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2340\/00015555-2706","article-title":"Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/archderm.1980.01640330073017","article-title":"Pemphigus in Hartford County, Connecticut, from 1972 to 1977","volume":"116","author":"Simon","year":"1980","journal-title":"Arch Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/jdv.15227","article-title":"Investigation of the predisposing factor of pemphigus and its clinical subtype through a genome-wide association and next generation sequence analysis","volume":"33","author":"Sun","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"Hubner","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12026-009-8153-2","article-title":"The prevalence of 30 ICD-10 autoimmune diseases in Denmark","volume":"47","author":"Eaton","year":"2010","journal-title":"Immunol Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J Autoimmun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jamadermatol.2018.5954","article-title":"Prevalence estimates for pemphigus in the United States: a sex- and age-adjusted population analysis","volume":"155","author":"Wertenteil","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-4632.2005.02038.x","article-title":"HLA-DRB1*0101 is associated with foliaceous pemphigus in Mexicans","volume":"44","author":"del Mar Saez-de-Ocariz","year":"2005","journal-title":"Int J Dermatol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0190-9622(89)70079-7","article-title":"Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology","volume":"20","author":"Diaz","year":"1989","journal-title":"J Am Acad Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jaut.2008.08.003","article-title":"Advances in pemphigus and its endemic pemphigus foliaceus (fogo selvagem) phenotype: a paradigm of human autoimmunity","volume":"31","author":"Culton","year":"2008","journal-title":"J Autoimmun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.0022-202X.2004.23438.x","article-title":"Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to fogo selvagem","volume":"123","author":"Diaz","year":"2004","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1087-0024.2004.00833.x","article-title":"Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem)","volume":"9","author":"Aoki","year":"2004","journal-title":"J Investig Dermatol Symp Proc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1610-0387.2010.07380.x","article-title":"Clinical and immunopathological spectrum of paraneoplastic pemphigus","volume":"8","author":"Zimmermann","year":"2010","journal-title":"J Dtsch Dermatol Ges."},{"key":"B24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1046\/j.1365-2133.2002.04992.x","article-title":"Paraneoplastic pemphigus in children and adolescents","volume":"147","author":"Mimouni","year":"2002","journal-title":"Br J Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0896-8411(02)00092-6","article-title":"Paraneoplastic pemphigus is associated with the DRB1*03 allele","volume":"20","author":"Martel","year":"2003","journal-title":"J Autoimmun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2007.08361.x","article-title":"Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus","volume":"158","author":"Liu","year":"2008","journal-title":"Br J Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/ddg.13688","article-title":"Bullous autoimmune dermatoses","volume":"16","author":"Hofmann","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1067\/mjd.2003.39","article-title":"History and clinical significance of mechanical symptoms in blistering dermatoses: a reappraisal","volume":"48","author":"Grando","year":"2003","journal-title":"J Am Acad Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fmed.2018.00227","article-title":"Involvement of nail apparatus in pemphigus vulgaris in ethnic poles is infrequent","volume":"5","author":"Pietkiewicz","year":"2018","journal-title":"Front Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1468-3083.2010.03939.x","article-title":"Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study","volume":"25","author":"Zaraa","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3389\/fimmu.2018.00779","article-title":"Humoral epitope spreading in autoimmune bullous diseases","volume":"9","author":"Didona","year":"2018","journal-title":"Front Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000018239","article-title":"Pemphigus erythematosus: detection of anti-desmoglein-1 antibodies by ELISA","volume":"199","author":"Gomi","year":"1999","journal-title":"Dermatology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-4632.2011.04868.x","article-title":"Paraneoplastic autoimmune multiorgan syndrome: 20 years after","volume":"50","author":"Czernik","year":"2011","journal-title":"Int J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1056\/NEJMcpc030016","article-title":"Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions","volume":"349","author":"Ahmed","year":"2003","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12262-015-1311-y","article-title":"Gastric cancer and paraneoplastic pemphigus","volume":"77","author":"Basir","year":"2015","journal-title":"Indian J Surg."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1046\/j.1365-2133.2001.04272.x","article-title":"Paraneoplastic pemphigus: the role of tumours and drugs","volume":"144","author":"Anhalt","year":"2001","journal-title":"Br J Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1440-0960.1995.tb00976.x","article-title":"Paraneoplastic pemphigus triggered by radiotherapy","volume":"36","author":"Lee","year":"1995","journal-title":"Australas J Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1365-4632.2009.03995.x","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome","volume":"48","author":"Sehgal","year":"2009","journal-title":"Int J Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clindermatol.2015.11.006","article-title":"Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica","volume":"34","author":"Broussard","year":"2016","journal-title":"Clin Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clindermatol.2013.11.003","article-title":"Autoimmune blistering dermatoses as systemic diseases","volume":"32","author":"Vassileva","year":"2014","journal-title":"Clin Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-0960.2005.126_1.x","article-title":"Paraneoplastic pemphigus: a brief update","volume":"46","author":"Wade","year":"2005","journal-title":"Australas J Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/JID.2015.408","article-title":"Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients","volume":"136","author":"Tsuchisaka","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1440-1843.2008.01397.x","article-title":"Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome","volume":"14","author":"Maldonado","year":"2009","journal-title":"Respirology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/jid.2011.390","article-title":"Desmoglein as a target in skin disease and beyond","volume":"132","author":"Amagai","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/15419061.2014.943397","article-title":"150(th) anniversary series: desmosomes and autoimmune disease, perspective of dynamic desmosome remodeling and its impairments in pemphigus","volume":"21","author":"Kitajima","year":"2014","journal-title":"Cell Commun Adhes."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/med.21310","article-title":"Desmosomes and extradesmosomal adhesive signaling contacts in pemphigus","volume":"34","author":"Waschke","year":"2014","journal-title":"Med Res Rev."},{"key":"B47","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.137.9.2835","article-title":"Defining the role of complement in experimental pemphigus vulgaris in mice","volume":"137","author":"Anhalt","year":"1986","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1006\/clin.1997.4408","article-title":"Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence","volume":"85","author":"Mascaro","year":"1997","journal-title":"Clin Immunol Immunopathol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0923-1811(00)00158-4","article-title":"Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J Dermatol Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.4049\/jimmunol.170.4.2170","article-title":"Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3","volume":"170","author":"Tsunoda","year":"2003","journal-title":"J Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J Clin Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.4049\/jimmunol.181.3.1825","article-title":"Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction","volume":"181","author":"Heupel","year":"2008","journal-title":"J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1600-0625.2006.00451.x","article-title":"IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris","volume":"15","author":"Muller","year":"2006","journal-title":"Exp Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"28820","DOI":"10.1038\/srep28820","article-title":"Loss of flotillin expression results in weakened desmosomal adhesion and Pemphigus vulgaris-like localisation of desmoglein-3 in human keratinocytes","volume":"6","author":"Vollner","year":"2016","journal-title":"Sci Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1074\/jbc.M512447200","article-title":"Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies","volume":"281","author":"Calkins","year":"2006","journal-title":"J Biol Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/jid.2008.339","article-title":"Disruption of desmosome assembly by monovalent human pemphigus vulgaris monoclonal antibodies","volume":"129","author":"Mao","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2133.2011.10463.x","article-title":"IgG-induced clustering of desmogleins 1 and 3 in skin of patients with pemphigus fits with the desmoglein nonassembly depletion hypothesis","volume":"165","author":"Oktarina","year":"2011","journal-title":"Br J Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/jid.2015.109","article-title":"Large-scale electron microscopy maps of patient skin and mucosa provide insight into pathogenesis of blistering diseases","volume":"135","author":"Sokol","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1172\/JCI23475","article-title":"Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction","volume":"115","author":"Waschke","year":"2005","journal-title":"J Clin Invest."},{"key":"B60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/jid.2013.224","article-title":"MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris","volume":"134","author":"Mao","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1074\/jbc.M110.172874","article-title":"p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris","volume":"286","author":"Mao","year":"2011","journal-title":"J Biol Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8936","DOI":"10.1074\/jbc.M109.087999","article-title":"p38MAPK signaling and desmoglein-3 internalization are linked events in pemphigus acantholysis","volume":"285","author":"Jolly","year":"2010","journal-title":"J Biol Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e50696","DOI":"10.1371\/journal.pone.0050696","article-title":"Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation","volume":"7","author":"Saito","year":"2012","journal-title":"PLoS ONE."},{"key":"B64","doi-asserted-by":"publisher","first-page":"711","DOI":"10.4049\/jimmunol.182.1.711","article-title":"Involvement of the apoptotic mechanism in pemphigus foliaceus autoimmune injury of the skin","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1038\/sj.emboj.7601224","article-title":"Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin","volume":"25","author":"Williamson","year":"2006","journal-title":"EMBO J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820130902943097","article-title":"Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris","volume":"38","author":"Satyam","year":"2009","journal-title":"Immunol Invest."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0148919","DOI":"10.1371\/journal.pone.0148919","article-title":"Increased frequency of T follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus","volume":"11","author":"Hennerici","year":"2016","journal-title":"PLoS ONE."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1006\/cyto.1999.0642","article-title":"Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid","volume":"12","author":"Bhol","year":"2000","journal-title":"Cytokine."},{"key":"B69","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-4362.2001.01083.x","article-title":"TNFalpha and IL-6 are mediators in the blistering process of pemphigus","volume":"40","author":"Lopez-Robles","year":"2001","journal-title":"Int J Dermatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/jid.2014.60","article-title":"No evidence of apoptotic cells in pemphigus acantholysis","volume":"134","author":"Janse","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.autrev.2009.01.011","article-title":"Apoptosis in pemphigus","volume":"8","author":"Schmidt","year":"2009","journal-title":"Autoimmun Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fimmu.2018.00370","article-title":"Soluble fas ligand is essential for blister formation in pemphigus","volume":"9","author":"Lotti","year":"2018","journal-title":"Front Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1046\/j.1523-1747.2003.12014.x","article-title":"Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8","volume":"120","author":"Puviani","year":"2003","journal-title":"J Invest Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e1006008","DOI":"10.1371\/journal.pgen.1006008","article-title":"Identification of a functional risk variant for pemphigus vulgaris in the ST18 gene","volume":"12","author":"Vodo","year":"2016","journal-title":"PLoS Genet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of autoimmune blistering diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00105-015-3723-9","article-title":"[Molecular diagnosis of autoimmune dermatoses]","volume":"67","author":"Hoffmann","year":"2016","journal-title":"Hautarzt."},{"key":"B78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/15665240113136660079","article-title":"Molecular diagnosis in autoimmune skin blistering conditions","volume":"14","author":"Otten","year":"2014","journal-title":"Curr Mol Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/exd.13409","article-title":"Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus","volume":"26","author":"Mindorf","year":"2017","journal-title":"Exp Dermatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjd.14877","article-title":"Paraneoplastic pemphigus with anti-BP180 autoantibodies and Castleman disease","volume":"176","author":"Maier","year":"2017","journal-title":"Br J Dermatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/PAT.0000000000000196","article-title":"Comparative study of five serological assays for the diagnosis of paraneoplastic pemphigus","volume":"47","author":"Kelly","year":"2015","journal-title":"Pathology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/exd.13488","article-title":"A novel lateral flow immunoassay for the rapid detection of anti-Dsg3 IgG serum autoantibodies in pemphigus vulgaris","volume":"27","author":"Schmidt","year":"2018","journal-title":"Exp Dermatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 Guideline for diagnosis and treatment\u2013guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","article-title":"The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis","volume":"73","author":"Atzmony","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer","year":"2012","journal-title":"Clin Dermatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-4362.1990.tb04765.x","article-title":"Pemphigus therapy with oral prednisolone regimens. A 5-year study","volume":"29","author":"Ratnam","year":"1990","journal-title":"Int J Dermatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/archderm.142.5.570","article-title":"Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial","volume":"142","author":"Mentink","year":"2006","journal-title":"Arch Dermatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1468-3083.2002.00461.x","article-title":"Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols","volume":"16","author":"Femiano","year":"2002","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/08916930600972008","article-title":"Pemphigus: a treatment update","volume":"39","author":"Dick","year":"2006","journal-title":"Autoimmunity."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1345\/aph.1A047","article-title":"Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus","volume":"36","author":"Toth","year":"2002","journal-title":"Ann Pharmacother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejphar.2005.12.052","article-title":"Corticosteroids: the drugs to beat","volume":"533","author":"Barnes","year":"2006","journal-title":"Eur J Pharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jaci.2006.01.032","article-title":"Update on glucocorticoid action and resistance","volume":"117","author":"Ito","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag."},{"key":"B97","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and future treatment options for pemphigus: is it time to move towards more effective treatments?","volume":"53","author":"Tavakolpour","year":"2017","journal-title":"Int Immunopharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1172\/JCI18384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J Clin Invest."},{"key":"B99","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1365-2133.2011.10575.x","article-title":"British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011","volume":"165","author":"Meggitt","year":"2011","journal-title":"Br J Dermatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1345\/aph.1P309","article-title":"Association between cancer and immunosuppressive therapy\u2013analysis of selected studies in pemphigus and pemphigoid","volume":"44","author":"Mabrouk","year":"2010","journal-title":"Ann Pharmacother."},{"key":"B101","doi-asserted-by":"publisher","first-page":"12601","DOI":"10.1111\/aji.12601","article-title":"Management of pemphigus disease in pregnancy","volume":"77","author":"Tavakolpour","year":"2017","journal-title":"Am J Reprod Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","author":"Chams-Davatchi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1468-3083.2010.03753.x","article-title":"High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study","volume":"25","author":"Chaidemenos","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus."},{"key":"B106","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaad.2008.08.049","article-title":"Mycophenolate mofetil in dermatology","volume":"60","author":"Orvis","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0190-9622(99)70203-3","article-title":"Mycophenolate mofetil in autoimmune and inflammatory skin disorders","volume":"40","author":"Nousari","year":"1999","journal-title":"J Am Acad Dermatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J Invest Dermatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch Dermatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1365-4362.1994.tb01003.x","article-title":"Treatment of oral pemphigus vulgaris","volume":"33","author":"Chrysomallis","year":"1994","journal-title":"Int J Dermatol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/ced.12073","article-title":"Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris","volume":"38","author":"Sharma","year":"2013","journal-title":"Clin Exp Dermatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","article-title":"Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study","volume":"3","author":"Rose","year":"2005","journal-title":"J Dtsch Dermatol Ges."},{"key":"B113","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4103\/0378-6323.55390","article-title":"Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris","volume":"75","author":"Sethy","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/0378-6323.104672","article-title":"Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a preliminary prospective randomized controlled study","volume":"79","author":"Parmar","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch Dermatol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1684\/ejd.2011.1611","article-title":"Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris","volume":"22","author":"Baum","year":"2012","journal-title":"Eur J Dermatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients","volume":"169","author":"Tran","year":"2013","journal-title":"Br J Dermatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/archderm.136.7.868","article-title":"Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus","volume":"136","author":"Ioannides","year":"2000","journal-title":"Arch Dermatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1610-0387.2012.07931.x","article-title":"Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases","volume":"10","author":"Kasperkiewicz","year":"2012","journal-title":"J Dtsch Dermatol Ges."},{"key":"B121","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/1756-185X.13511","article-title":"Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: a single-center experience in Taiwan","volume":"22","author":"Wang","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","article-title":"B cell modulation strategies in autoimmune diseases: new concepts","volume":"9","author":"Musette","year":"2018","journal-title":"Front Immunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"42427","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem."},{"key":"B127","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.blre.2017.05.002","article-title":"Dancing partners at the ball: rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era","volume":"31","author":"Butler","year":"2017","journal-title":"Blood Rev."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","article-title":"Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives","volume":"9","author":"Bezombes","year":"2011","journal-title":"Mol Cancer Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2567.2005.02213.x","article-title":"Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking","volume":"116","author":"Unruh","year":"2005","journal-title":"Immunology."},{"key":"B131","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","article-title":"A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections","volume":"97","author":"Seyfizadeh","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","article-title":"Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays","volume":"526","author":"Golay","year":"2012","journal-title":"Arch Biochem Biophys."},{"key":"B133","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/1535-7163.MCT-15-0335","article-title":"Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells","volume":"15","author":"Velmurugan","year":"2016","journal-title":"Mol Cancer Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs."},{"key":"B136","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"93222","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/ijd.13807","article-title":"Bullous eruption in a patient with B-cell chronic lymphocytic leukemia: a diagnostic challenge","volume":"56","author":"Maglie","year":"2017","journal-title":"Int J Dermatol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00403-013-1355-4","article-title":"A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab","volume":"306","author":"Leshem","year":"2014","journal-title":"Arch Dermatol Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/MPH.0000000000000485","article-title":"Rituximab-induced cytokine storm in the absence of overt lymphoproliferative disease","volume":"38","author":"Williams","year":"2016","journal-title":"J Pediatr Hematol Oncol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e227091","DOI":"10.1136\/bcr-2018-227091","article-title":"Citrobacter freundii sepsis in an immunosuppressed patient with pemphigus vulgaris","volume":"11","author":"Ferranti","year":"2018","journal-title":"BMJ Case Rep."},{"key":"B145","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000478078","article-title":"Bullous diseases","volume":"53","author":"Corbaux","year":"2018","journal-title":"Curr Probl Dermatol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B147","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4103\/2229-5178.169722","article-title":"Rituximab therapy in a case of pemphigus vulgaris triggering herpes simplex infection at varied sites","volume":"6","author":"Chotaliya","year":"2015","journal-title":"Indian Dermatol Online J."},{"key":"B148","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2340\/00015555-1429","article-title":"Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone","volume":"93","author":"Chiu","year":"2013","journal-title":"Acta Derm Venereol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1684\/ejd.2018.3373","article-title":"Pneumocystis jirovecii pneumonia infection in pemphigus patients treated with rituximab: an observational nationwide epidemiological study in Taiwan","volume":"28","author":"Wei","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1038\/s41598-018-26743-4","article-title":"Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients","volume":"8","author":"Wei","year":"2018","journal-title":"Sci Rep."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.transproceed.2017.04.020","article-title":"Combination of echinocandins and trimethoprim\/sulfamethoxazole for the treatment of pneumocystis jiroveci pneumonia after heart transplantation","volume":"49","author":"Lu","year":"2017","journal-title":"Transplant Proc."},{"key":"B152","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1111\/jdv.14144","article-title":"Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab","volume":"31","author":"Wei","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/jdv.15237","article-title":"Assessment of serious infections in pemphigus and pemphigoid by a national registry","volume":"32","author":"Maglie","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B155","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/bjd.13355","article-title":"Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses","volume":"171","author":"Keith","year":"2014","journal-title":"Br J Dermatol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/0378-6323.168912","article-title":"The controversy of hepatitis C and rituximab: a multidisciplinary dilemma with implications for patients with pemphigus","volume":"82","author":"Amber","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.anai.2016.05.013","article-title":"Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist","volume":"117","author":"Khan","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review","volume":"5","author":"Levin","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B160","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/rheumatology\/kex403","article-title":"Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data","volume":"57","author":"Salmon","year":"2018","journal-title":"Rheumatology."},{"key":"B161","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1714146","article-title":"Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab","volume":"378","author":"Crowley","year":"2018","journal-title":"N Engl J Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/eci.11.75","article-title":"Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies","volume":"8","author":"Hong","year":"2012","journal-title":"Expert Rev Clin Immunol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"B165","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjh.15177","article-title":"Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies","volume":"184","author":"Vendramin","year":"2018","journal-title":"Br J Haematol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/DAD.0000000000000356","article-title":"Rituximab-induced serum sickness-like reaction: a histopathologic viewpoint","volume":"38","author":"Succaria","year":"2016","journal-title":"Am J Dermatopathol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.13823","article-title":"Paradoxical worsening of pemphigus vulgaris following rituximab therapy","volume":"173","author":"Feldman","year":"2015","journal-title":"Br J Dermatol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","article-title":"Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed","volume":"31","author":"Belgi","year":"2006","journal-title":"Clin Exp Dermatol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3389\/fimmu.2018.00810","article-title":"Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions","volume":"9","author":"Alaibac","year":"2018","journal-title":"Front Immunol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"347","DOI":"10.18176\/jiaci.0283","article-title":"Persistent B lymphocyte depletion after an ultralow dose of rituximab for pemphigus vulgaris","volume":"28","author":"Lazzarotto","year":"2018","journal-title":"J Investig Allergol Clin Immunol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1056\/NEJMc1508234","article-title":"Long-term remissions in recalcitrant pemphigus vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N Engl J Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med."},{"key":"B177","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2018.05.1252","article-title":"Rituximab treatment of pemphigus foliaceus\u2014a retrospective study of 12 patients","volume":"5","author":"Palacios-Alvarez","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/bjd.13586","article-title":"Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature","volume":"172","author":"de Sena Nogueira Maehara","year":"2015","journal-title":"Br J Dermatol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/bjd.15947","article-title":"Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus","volume":"177","author":"Murrell","year":"2017","journal-title":"Br J Dermatol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations by an international panel of experts","volume":"2","author":"Murrell","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ddg.12606","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Eming","year":"2015","journal-title":"J Dtsch Dermatol Ges."},{"key":"B189","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/1744666X.4.3.351","article-title":"Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus","volume":"4","author":"Vezzoli","year":"2008","journal-title":"Expert Rev Clin Immunol."},{"key":"B190","first-page":"269","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus","volume":"137","author":"Borradori","year":"2001","journal-title":"Arch Dermatol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::aid-ajh1032>3.0.co;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am J Hematol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1468-3083.2005.01345.x","article-title":"Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature","volume":"20","author":"Barnadas","year":"2006","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s12185-017-2305-2","article-title":"Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy","volume":"106","author":"Lee","year":"2017","journal-title":"Int J Hematol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00277-017-3008-8","article-title":"Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus","volume":"96","author":"Kikuchi","year":"2017","journal-title":"Ann Hematol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3960\/jslrt.55.83","article-title":"Rituximab monotherapy and rituximab-containing chemotherapy were effective for paraneoplastic pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans","volume":"55","author":"Hirano","year":"2015","journal-title":"J Clin Exp Hematop."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.autrev.2018.04.008","article-title":"Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus","volume":"17","author":"Amber","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B197","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1684\/ejd.2008.0528","article-title":"Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia","volume":"18","author":"Schierl","year":"2008","journal-title":"Eur J Dermatol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1111\/jdv.14500","article-title":"Paraneoplastic pemphigus seen in four patients with haematological malignancies formerly treated with rituximab","volume":"32","author":"Baykal","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bjd.17577","article-title":"Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies","volume":"180","author":"Kwatra","year":"2019","journal-title":"Br J Dermatol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology."},{"key":"B202","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert","year":"2018","journal-title":"Immunotherapy."},{"key":"B203","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges."},{"key":"B205","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","volume":"166","author":"Feldman","year":"2012","journal-title":"Br J Dermatol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/jid.2008.192","article-title":"B-cell-directed therapy for inflammatory skin diseases","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bjd.17591","article-title":"Clinical and immunological features of pemphigus relapse","volume":"180","author":"Ujiie","year":"2018","journal-title":"Br J Dermatol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","article-title":"Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris","volume":"166","author":"Behzad","year":"2012","journal-title":"Br J Dermatol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","article-title":"A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab","volume":"79","author":"Saleh","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"e12814","DOI":"10.1111\/dth.12814","article-title":"Mucosal involvement is a risk factor for poor clinical outcomes and relapse in patients with pemphigus treated with rituximab","volume":"32","author":"Cho","year":"2019","journal-title":"Dermatol Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"3523057","DOI":"10.1155\/2016\/3523057","article-title":"Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses","volume":"2016","author":"Dourmishev","year":"2016","journal-title":"Int J Inflamm."},{"key":"B212","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ajd.12422","article-title":"IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects","volume":"57","author":"Svecova","year":"2016","journal-title":"Australas J Dermatol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","volume":"166","author":"Kasperkiewicz","year":"2012","journal-title":"Br J Dermatol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","volume":"158","author":"Shimanovich","year":"2008","journal-title":"Br J Dermatol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMc1215489","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"368","author":"Gelfand","year":"2013","journal-title":"N Engl J Med."},{"key":"B218","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2340\/00015555-0249","article-title":"Intravenous immunoglobulin: properties, mode of action and practical use in dermatology","volume":"87","author":"Prins","year":"2007","journal-title":"Acta Derm Venereol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venous and arterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis."},{"key":"B220","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med."},{"key":"B221","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0272-6386(95)90003-9","article-title":"Acute renal failure associated with immunoglobulin therapy","volume":"25","author":"Cantu","year":"1995","journal-title":"Am J Kidney Dis."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","article-title":"Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus","volume":"148","author":"Schmidt","year":"2003","journal-title":"Br J Dermatol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1684\/ejd.2014.2483","article-title":"Pemphigus vulgaris: approach to treatment","volume":"25","author":"Sinha","year":"2015","journal-title":"Eur J Dermatol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/08916930600972040","article-title":"Immunoadsorption in pemphigus","volume":"39","author":"Eming","year":"2006","journal-title":"Autoimmunity."},{"key":"B225","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","article-title":"Immunoadsorption in dermatology","volume":"302","author":"Schmidt","year":"2010","journal-title":"Arch Dermatol Res."},{"key":"B226","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg","year":"2012","journal-title":"Ther Apher Dial."},{"key":"B227","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","article-title":"Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases","volume":"5","author":"Zillikens","year":"2007","journal-title":"J Dtsch Dermatol Ges."},{"key":"B228","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/exd.12355","article-title":"Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins","volume":"23","author":"Langenhan","year":"2014","journal-title":"Exp Dermatol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3389\/fimmu.2018.01935","article-title":"Immunoadsorption of desmoglein-3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice","volume":"9","author":"Hofrichter","year":"2018","journal-title":"Front Immunol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1525-1594.2006.00189.x","article-title":"Clearance studies during subsequent sessions of double filtration plasmapheresis","volume":"30","author":"Yeh","year":"2006","journal-title":"Artif Organs."},{"key":"B231","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2340\/00015555-1444","article-title":"Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus","volume":"93","author":"Kasuya","year":"2013","journal-title":"Acta Derm Venereol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1744-9987.12557","article-title":"Evaluating the efficacy of double-filtration plasmapheresis in treating five patients with drug-resistant pemphigus","volume":"21","author":"Higashihara","year":"2017","journal-title":"Ther Apher Dial."},{"key":"B233","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus","volume":"130","author":"Lunardon","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights."},{"key":"B235","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14712598.2015.1055241","article-title":"Ofatumumab in the treatment of non-Hodgkin's lymphomas","volume":"15","author":"Karlin","year":"2015","journal-title":"Expert Opin Biol Ther."},{"key":"B236","first-page":"1338","article-title":"Successful treatment of pemphigus vulgaris with ofatumumab","volume":"17","author":"Rapp","year":"2018","journal-title":"J Drugs Dermatol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjh.15132","article-title":"New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies","volume":"180","author":"Meyer","year":"2018","journal-title":"Br J Haematol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","article-title":"Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?","volume":"21","author":"Reddy","year":"2016","journal-title":"Drug Discov Today."},{"key":"B240","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/10428194.2018.1498490","article-title":"Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders","volume":"60","author":"Prica","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology."},{"key":"B242","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/1744666X.2017.1291343","article-title":"Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)","volume":"13","author":"Stohl","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B244","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/82_2015_478","article-title":"BTK signaling in B cell differentiation and autoimmunity","volume":"393","author":"Corneth","year":"2016","journal-title":"Curr Top Microbiol Immunol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4049\/jimmunol.1600208","article-title":"Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis","volume":"197","author":"Corneth","year":"2016","journal-title":"J Immunol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2169\/internalmedicine.0578-17","article-title":"Paraneoplastic pemphigus associated with B-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab","volume":"57","author":"Ito","year":"2018","journal-title":"Intern Med."},{"key":"B248","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.3324\/haematol.2017.168930","article-title":"The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-kappaB mutational status","volume":"102","author":"Vidal-Crespo","year":"2017","journal-title":"Haematologica."},{"key":"B249","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2133.1980.tb07250.x","article-title":"The potassium iodide patch test in the dermatitis herpetiformis in relation to treatment with a gluten-free diet and dapsone","volume":"103","author":"Haffenden","year":"1980","journal-title":"Br J Dermatol."},{"key":"B250","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood."},{"key":"B251","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA."},{"key":"B252","doi-asserted-by":"publisher","first-page":"E207","DOI":"10.3390\/jcm8020207","article-title":"Chimeric antigen receptor T-cells: the future is now","volume":"8","author":"McHayleh","year":"2019","journal-title":"J Clin Med."},{"key":"B253","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood."},{"key":"B254","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B255","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3389\/fimmu.2018.03062","article-title":"Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy","volume":"9","author":"Chuntova","year":"2018","journal-title":"Front Immunol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3892\/ol.2018.8946","article-title":"Combination therapy: a feasibility strategy for CAR-T cell therapy in the treatment of solid tumors","volume":"16","author":"Xu","year":"2018","journal-title":"Oncol Lett."},{"key":"B257","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/exd.13792","article-title":"CAR-T cell therapy in melanoma: a future success story?","volume":"27","author":"Simon","year":"2018","journal-title":"Exp Dermatol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd.2016.180","article-title":"Autoimmune diseases: CAR-T cells take aim at autoimmunity","volume":"15","author":"Flemming","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B259","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/imt-2017-0028","article-title":"Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities","volume":"9","author":"Wegner","year":"2017","journal-title":"Immunotherapy."},{"key":"B260","doi-asserted-by":"publisher","first-page":"e41769","DOI":"10.1371\/journal.pone.0041769","article-title":"Pathogenicity of autoantibodies in anti-p200 pemphigoid","volume":"7","author":"Vafia","year":"2012","journal-title":"PLoS ONE."},{"key":"B261","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B262","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst."},{"key":"B263","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.3389\/fimmu.2018.02740","article-title":"CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success","volume":"9","author":"Long","year":"2018","journal-title":"Front Immunol."},{"key":"B264","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.jid.2018.09.002","article-title":"Research techniques made simple: CAR T-cell therapy","volume":"138","author":"Siddiqi","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B265","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"B266","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nbt.3670","article-title":"Precision medicine for autoimmune disease","volume":"34","author":"Chatenoud","year":"2016","journal-title":"Nat Biotechnol."},{"key":"B267","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B268","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B269","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/jdv.12832","article-title":"Rapid transition from pemphigus vulgaris to pemphigus foliaceus","volume":"30","author":"Ito","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1468-3083.2007.02298.x","article-title":"Pemphigus foliaceus evolving into pemphigus vulgaris: a probable example of \u2018intermolecular epitope spreading' confirmed by enzyme-linked immunosorbent assay study","volume":"22","author":"Pigozzi","year":"2008","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B271","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B272","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B273","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) treg: a promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Immunol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/exd.12919","article-title":"Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris","volume":"25","author":"Schmidt","year":"2016","journal-title":"Exp Dermatol."},{"key":"B275","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation."},{"key":"B276","doi-asserted-by":"publisher","first-page":"1582059","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: costs, comparisons and commentary","volume":"2019","author":"Hay","year":"2019","journal-title":"J Med Econ."},{"key":"B277","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B278","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1091\/mbc.e07-02-0101","article-title":"Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells","volume":"19","author":"Goebl","year":"2008","journal-title":"Mol Biol Cell."},{"key":"B279","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol Sci."},{"key":"B280","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell Mol Life Sci."},{"key":"B281","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.0022-202X.2004.23542.x","article-title":"Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes","volume":"124","author":"Cauza","year":"2005","journal-title":"J Invest Dermatol."},{"key":"B282","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest."},{"key":"B283","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0002-9440(10)61239-4","article-title":"Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus","volume":"167","author":"Arredondo","year":"2005","journal-title":"Am J Pathol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"23826","DOI":"10.1074\/jbc.M115.668061","article-title":"Critical role of the neonatal Fc receptor (FcRn) in the pathogenic action of antimitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris","volume":"290","author":"Chen","year":"2015","journal-title":"J Biol Chem."},{"key":"B285","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3389\/fimmu.2018.01788","article-title":"The p.Arg435His variation of IgG3 with high affinity to FcRn is associated with susceptibility for pemphigus vulgaris-analysis of four different ethnic cohorts","volume":"9","author":"Recke","year":"2018","journal-title":"Front Immunol."},{"key":"B286","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest."},{"key":"B287","doi-asserted-by":"publisher","first-page":"17","DOI":"10.23750\/abm.v89i9-S.7953","article-title":"Genetic susceptibilty and celiac disease: what role do HLA haplotypes play?","volume":"89","author":"Sciurti","year":"2018","journal-title":"Acta Biomed."},{"key":"B288","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00403-006-0661-5","article-title":"Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases","volume":"298","author":"Echigo","year":"2006","journal-title":"Arch Dermatol Res."},{"key":"B289","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/exd.12229","article-title":"Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris","volume":"22","author":"Amber","year":"2013","journal-title":"Exp Dermatol."},{"key":"B290","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.4049\/jimmunol.1401081","article-title":"Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells","volume":"193","author":"Eming","year":"2014","journal-title":"J Immunol."},{"key":"B291","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","article-title":"TH1\/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus","volume":"142","author":"Schmidt","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.4049\/jimmunol.181.2.1526","article-title":"Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris","volume":"181","author":"Takahashi","year":"2008","journal-title":"J Immunol."},{"key":"B293","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clim.2009.11.006","article-title":"Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3","volume":"134","author":"Nagel","year":"2010","journal-title":"Clin Immunol."},{"key":"B294","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.12.007","article-title":"Pharmacological advances in pemphigoid","volume":"46","author":"Maglie","year":"2019","journal-title":"Curr Opin Pharmacol."},{"key":"B295","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B296","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/dxr020","article-title":"Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris","volume":"23","author":"Yokoyama","year":"2011","journal-title":"Int Immunol."},{"key":"B297","first-page":"497","article-title":"Seeking approval: present and future therapies for pemphigus vulgaris","volume":"9","author":"Mao","year":"2008","journal-title":"Curr Opin Investig Drugs."},{"key":"B298","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"Invest Dermatol."},{"key":"B299","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.jid.5700059","article-title":"Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: a step toward antigen-specific therapy?","volume":"126","author":"Liu","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B300","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B301","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.jid.2017.05.032","article-title":"Pivotal role of lesional and perilesional T\/B lymphocytes in pemphigus pathogenesis","volume":"137","author":"Yuan","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B302","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther."},{"key":"B303","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0772-7","article-title":"JAK-STAT Signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"key":"B304","first-page":"1","article-title":"Tofacitinib in the treatment of rheumatoid arthritis and chronic plaque psoriasis","volume":"22","author":"Gupta","year":"2017","journal-title":"Skin Therapy Lett."},{"key":"B305","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","article-title":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","volume":"78","author":"Putterman","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B306","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/bjd.15721","article-title":"Inhibition of p38MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis","volume":"177","author":"Egu","year":"2017","journal-title":"Br J Dermatol."},{"key":"B307","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1097\/BCR.0b013e31828a8d6e","article-title":"Delayed topical p38 MAPK inhibition attenuates full-thickness burn wound inflammatory signaling","volume":"35","author":"Carter","year":"2014","journal-title":"J Burn Care Res."},{"key":"B308","doi-asserted-by":"publisher","first-page":"e92253","DOI":"10.1172\/jci.insight.92253","article-title":"Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes","volume":"2","author":"Mao","year":"2017","journal-title":"JCI Insight."},{"key":"B309","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaad.2011.01.029","article-title":"Sirolimus for acute pemphigus vulgaris: a case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection","volume":"65","author":"Grando","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B310","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.jaad.2012.04.032","article-title":"Topical sirolimus for oral pemphigus vulgaris: 3 unresponsive cases","volume":"67","author":"Poot","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B311","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-12-0191","article-title":"First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy","volume":"2","author":"Sen","year":"2012","journal-title":"Cancer Discov."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T14:57:59Z","timestamp":1694962679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":311,"alternative-id":["10.3389\/fimmu.2019.01418"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01418","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"article-number":"1418"}}